SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, LODE MAKING ME RICH, homeslice10, lasers, AyeEye
Search This Board:
Last Post: 9/2/2015 1:42:40 AM - Followers: 647 - Board type: Free - Posts Today: 1


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
News News Alert: Ocata Therapeutics Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenito... 09/01/2015 09:15:00 AM
PostSubject
#88104  Sticky Note I had to register just to make a comment. Enough-Already 08/26/15 05:35:48 PM
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#88387   MAJOR ACT OF DESPERATION BY SHORTS Enough-Already 09/02/15 01:42:40 AM
#88386   No.. they dont expect any revenue until 2020 fulleroots 09/01/15 05:07:16 PM
#88385   The sbir grant is typically 150k for phase homeslice10 09/01/15 04:45:53 PM
#88384   Do Grants count as Revenue? dsroyal91 09/01/15 04:22:16 PM
#88383   Couldn't hold the 50 DMA AGAIN, SOLD OFF Captain Kirk 09/01/15 04:15:16 PM
#88381   Smart move. farviewhill 09/01/15 02:50:14 PM
#88380   The best score we have seen in this elysse1kittycat 09/01/15 02:45:49 PM
#88379   Sure is a long ways to go, hope Gastrodamas 09/01/15 02:34:46 PM
#88378   Yea there gonna take it down again soon fulleroots 09/01/15 02:17:15 PM
#88377   OCAT Chart conix 09/01/15 02:11:03 PM
#88376   Since I don't see Chuck here today. Shiskabill 09/01/15 01:48:59 PM
#88375   The NIH grant makes me feel a little Doktornolittle 09/01/15 01:28:42 PM
#88374   Well, the cheap bowl of soap is now ison929 09/01/15 01:00:27 PM
#88373   Yes that it will Gastrodamas 09/01/15 12:59:17 PM
#88372   Looks like FAZ is doing as well as we. Gastrodamas 09/01/15 12:57:54 PM
#88371   I can't wait until 3:00 pm we should Shiskabill 09/01/15 12:42:39 PM
#88369   SOLD OFF LIKE A CHEAP BOWL OF SOUP, Captain Kirk 09/01/15 12:16:00 PM
#88368   My mistake , drawer in the corner. Gastrodamas 09/01/15 12:14:52 PM
#88367   Remember years ago our comments about sticking Gastrodamas 09/01/15 12:13:23 PM
#88366   Wonder if the guys who took it down Gastrodamas 09/01/15 12:10:21 PM
#88365   This is just the beginning Folks. Goodbuddy4863 09/01/15 11:46:05 AM
#88364   No, no, all is very, very bad like allways.LOL runcaly 09/01/15 11:46:05 AM
#88363   OCAT volume is almost at daily average. Shiskabill 09/01/15 11:05:54 AM
#88361   Bailed out on my trading position...now looking for fulleroots 09/01/15 11:02:45 AM
#88352   Three Blind Mice can now see! lol FSAIL52 09/01/15 10:34:47 AM
#88351   The stock IS NOT "UP" LOL???????????????? Captain Kirk 09/01/15 10:29:05 AM
#88349   Nobel Prizes usually come several years after the elllk 09/01/15 09:52:33 AM
#88348  Restored Another NIH Grant for Ocata. Wow. Enough-Already 09/01/15 09:48:27 AM
#88347   Reetala Dr. Lanza has to be considered for Shiskabill 09/01/15 09:48:00 AM
#88345   Some other companies are having problems with tumor elllk 09/01/15 09:47:54 AM
#88344   Ocata saving the day again so far with elysse1kittycat 09/01/15 09:40:10 AM
#88343   Ocata Therapeutics Receives SBIR Grant from the NIH’s Reetala 09/01/15 09:21:21 AM
#88342   I think that (tumor concern) was what phase art2426 09/01/15 08:55:36 AM
#88341   Do you all realize how much DATA OCATa dsroyal91 09/01/15 07:31:33 AM
#88340   I read about this earlier. dsroyal91 08/31/15 10:31:48 PM
#88338   Another catalyst could involve a patent application that AyeEye 08/31/15 09:44:33 PM
#88337   Form T alot of buying.. Gastrodamas 08/31/15 09:29:42 PM
#88336   Why do people try to forecast a near dsroyal91 08/31/15 09:01:45 PM
#88335   Im looking for a nice day trade, hopefully fulleroots 08/31/15 08:44:47 PM
#88334   I bet THEY HAVE INJECTED A PATIENT!!! dsroyal91 08/31/15 08:21:21 PM
#88333   You are wrong!!! dsroyal91 08/31/15 08:15:21 PM
#88331   Quote LOL, "What's this then??? Captain Kirk 08/31/15 07:53:05 PM
#88330   And THAT'$ THE REST OF THE STORY!!! dsroyal91 08/31/15 07:33:51 PM
#88329   What's this then??? dsroyal91 08/31/15 07:31:59 PM
#88328   Quote NO BS LOL, "Got a link that Captain Kirk 08/31/15 06:04:01 PM
#88326   TodY was the opposite of last week when elysse1kittycat 08/31/15 04:12:56 PM
#88325   My God, so what, runcaly 08/31/15 04:05:05 PM
#88324   QUOTE BS LOL bballerfanatic 08/31/15 04:01:14 PM
#88322   Sorry, don't understand your post. Would you expand farviewhill 08/31/15 03:29:30 PM
#88321   I hate a predictable stock. Gastrodamas 08/31/15 02:30:57 PM
PostSubject